Panel to evaluate FDA pharmacogenomics paper
Executive Summary
FDA will convene its Pharmaceutical Science and Clinical Pharmacology Advisory Committee March 18 to evaluate the agency's clinical pharmacogenomics concept paper. Industry is requesting that FDA clarify elements of the companion guidance, and the panel will discuss issues pertaining to collection of samples and applications of pharmacogenomics in clinical development (1"The Pink Sheet," Dec. 10, 2007, p. 18). The panel also will address qualitative clinical pharmacology. On March 19, the panel will discuss the renal impairment concept paper...
You may also be interested in...
Pharmacogenomics Draft Guidance Needs Clarification, Industry Tells FDA
Industry is pressing FDA to enhance the utility of its "companion guidance" on pharmacogenomic data submissions as the agency refines the draft document
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.